株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

子宮体癌:パイプライン製品の分析

Endometrial Cancer - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 229742
出版日 ページ情報 英文 533 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.24円で換算しております。
Back to Top
子宮体癌:パイプライン製品の分析 Endometrial Cancer - Pipeline Review, H1 2017
出版日: 2017年06月13日 ページ情報: 英文 533 Pages
概要

子宮体癌(子宮内膜癌)とは、子宮の内膜で発症する癌を指し、子宮癌の中でも最も一般的なものです。子宮体癌の実際の原因はまだ不明ですが、エストロゲンの数値上昇が何らかの役割を果たしていると見られています。というのも、エストロゲンは子宮内膜の発達を促進する働きがあるからです。主な症状として、不正出血(中間期出血や、閉経後の少量の出血を含む)や、40歳以降の膣出血(期間が極度に長く頻繁で症状が重いもの)、下腹部の痛み、骨盤のけいれん、閉経後の白色/透明の膣分泌物などが挙げられます。

当レポートでは、世界各国での子宮体癌(子宮内膜癌)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

子宮体癌の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

子宮体癌:企業で開発中の治療薬

子宮体癌:大学/機関で研究中の治療薬

子宮体癌:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

子宮体癌:企業で開発中の製品

子宮体癌:大学/機関で研究中の製品

子宮体癌の治療薬開発に従事している企業

  • Ability Pharmaceuticals, S.L.
  • Advenchen Laboratories, LLC
  • Aeterna Zentaris Inc.
  • Arno Therapeutics, Inc.
  • ArQule, Inc.
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • BeiGene, Ltd.
  • BioNTech AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cellceutix Corporation
  • Critical Outcome Technologies Inc.
  • エーザイ
  • Eli Lilly and Company
  • Esperance Pharmaceuticals, Inc.
  • Exelixis, Inc.
  • Galena Biopharma, Inc.
  • Genmab A/S
  • GlaxoSmithKline Plc
  • Gradalis Inc.
  • Horizon Pharma Plc
  • ImmunoGen, Inc.
  • Incyte Corporation
  • Karyopharm Therapeutics, Inc.
  • Medivation, Inc.
  • Merck & Co., Inc.
  • Merck KGaA
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • OncoHoldings, Inc.
  • 大塚ホールディングス
  • Pfizer Inc.
  • Pharma Mar, S.A.
  • Pharmsynthez
  • Pivot Pharmaceuticals Inc
  • Puma Biotechnology, Inc.
  • Sanofi
  • Shenogen Pharma Group Ltd.
  • Synthon Holdings BV
  • Vertex Pharmaceuticals Incorporated
  • Vyriad

子宮体癌:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

子宮体癌:最近のパイプライン動向

子宮体癌:休止中のプロジェクト

子宮体癌:開発が中止された製品

子宮体癌:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9395IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer - Pipeline Review, H1 2017, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape.

Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometrial Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Endometrial Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 37, 35, 1 and 15 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Endometrial Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Endometrial Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Endometrial Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Endometrial Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Endometrial Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Endometrial Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Endometrial Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Endometrial Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Endometrial Cancer - Overview
  • Endometrial Cancer - Therapeutics Development
  • Endometrial Cancer - Therapeutics Assessment
  • Endometrial Cancer - Companies Involved in Therapeutics Development
  • Endometrial Cancer - Drug Profiles
  • Endometrial Cancer - Dormant Projects
  • Endometrial Cancer - Discontinued Products
  • Endometrial Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Endometrial Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Endometrial Cancer - Pipeline by AbbVie Inc, H1 2017
  • Endometrial Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2017
  • Endometrial Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
  • Endometrial Cancer - Pipeline by Aeterna Zentaris Inc, H1 2017
  • Endometrial Cancer - Pipeline by ArQule Inc, H1 2017
  • Endometrial Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
  • Endometrial Cancer - Pipeline by AstraZeneca Plc, H1 2017
  • Endometrial Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
  • Endometrial Cancer - Pipeline by Bayer AG, H1 2017
  • Endometrial Cancer - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
  • Endometrial Cancer - Pipeline by BioNTech AG, H1 2017
  • Endometrial Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017
  • Endometrial Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Endometrial Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Endometrial Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017
  • Endometrial Cancer - Pipeline by Cellceutix Corp, H1 2017
  • Endometrial Cancer - Pipeline by Critical Outcome Technologies Inc, H1 2017
  • Endometrial Cancer - Pipeline by CytomX Therapeutics Inc, H1 2017
  • Endometrial Cancer - Pipeline by Eisai Co Ltd, H1 2017
  • Endometrial Cancer - Pipeline by Eli Lilly and Company, H1 2017
  • Endometrial Cancer - Pipeline by Endocyte Inc, H1 2017
  • Endometrial Cancer - Pipeline by Esperance Pharmaceuticals Inc, H1 2017
  • Endometrial Cancer - Pipeline by Exelixis Inc, H1 2017
  • Endometrial Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Endometrial Cancer - Pipeline by Galena Biopharma Inc, H1 2017
  • Endometrial Cancer - Pipeline by GamaMabs Pharma SA, H1 2017
  • Endometrial Cancer - Pipeline by Genmab A/S, H1 2017
  • Endometrial Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Endometrial Cancer - Pipeline by Glycotope GmbH, H1 2017
  • Endometrial Cancer - Pipeline by Gradalis Inc, H1 2017
  • Endometrial Cancer - Pipeline by Horizon Pharma Plc, H1 2017
  • Endometrial Cancer - Pipeline by Immunocore Ltd, H1 2017
  • Endometrial Cancer - Pipeline by ImmunoGen Inc, H1 2017
  • Endometrial Cancer - Pipeline by Immunomedics Inc, H1 2017
  • Endometrial Cancer - Pipeline by Incyte Corp, H1 2017
  • Endometrial Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Endometrial Cancer - Pipeline by Lion Biotechnologies Inc, H1 2017
  • Endometrial Cancer - Pipeline by MedImmune LLC, H1 2017
  • Endometrial Cancer - Pipeline by Merck & Co Inc, H1 2017
  • Endometrial Cancer - Pipeline by Merck KGaA, H1 2017
  • Endometrial Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
  • Endometrial Cancer - Pipeline by Merus NV, H1 2017
  • Endometrial Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Endometrial Cancer - Pipeline by Novartis AG, H1 2017
  • Endometrial Cancer - Pipeline by Pfizer Inc, H1 2017
  • Endometrial Cancer - Pipeline by Pharma Mar SA, H1 2017
  • Endometrial Cancer - Pipeline by Pivot Pharmaceuticals Inc, H1 2017
  • Endometrial Cancer - Pipeline by Puma Biotechnology Inc, H1 2017
  • Endometrial Cancer - Pipeline by Sanofi, H1 2017
  • Endometrial Cancer - Pipeline by Shenogen Pharma Group Ltd, H1 2017
  • Endometrial Cancer - Pipeline by Sigma-Tau SpA, H1 2017
  • Endometrial Cancer - Pipeline by Syndax Pharmaceuticals Inc, H1 2017
  • Endometrial Cancer - Pipeline by Synthon Holdings BV, H1 2017
  • Endometrial Cancer - Pipeline by Tesaro Inc, H1 2017
  • Endometrial Cancer - Dormant Projects, H1 2017
  • Endometrial Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Endometrial Cancer - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Endometrial Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top